Results 11 to 20 of about 143,948 (293)

Surgical Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA Guideline Amendment 2020.

Journal of Urology, 2020
PURPOSE The AUA Guideline panel provides evidence-based recommendations for the surgical management of male lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH).
J. Parsons, P. Dahm, T. Köhler, L. Lerner, T. Wilt   +4 more
semanticscholar   +1 more source

Benign prostatic hyperplasia – what do we know?

BJU International, 2020
To present historical and contemporary hypotheses on the pathogenesis of benign prostatic hyperplasia (BPH), and the potential implications for current medical therapies.
C. Devlin, M. Simms, N. Maitland
semanticscholar   +1 more source

The rising worldwide impact of benign prostatic hyperplasia

BJU International, 2020
To describe the trend in the impact of lower urinary tract symptoms attributed to benign prostatic hyperplasia (LUTS/BPH) on a global scale using the Global Burden of Disease (GBD) database.
B. Launer, K. McVary, W. Ricke, G. Lloyd
semanticscholar   +1 more source

The Influencing Role of Diabetes Mellitus and Hypertension in the Establishment of Benign Prostatic Hyperplasia

Journal of Nobel Medical College, 2020
Background: Benign prostatic hyperplasia is regarded as non-malignant growth of prostatic tissueIt is the most common benign tumor in men, and the incidence is age related. In men aged more than 50 years, it is the fourth most prevalent disease.
Ram Sagar Shah, Rabindra Tamang
doaj   +1 more source

Current Treatment for Benign Prostatic Hyperplasia.

Deutsches Ärzteblatt International, 2020
BACKGROUND Benign prostatic hyperplasia (BPH) is characterized by the occurrence of.disorders of urine storage and bladder emptying. Most men over the age of 60 years are affected to some degree.
A. Miernik, C. Gratzke
semanticscholar   +1 more source

Role of gangliosides in prostate pathology [PDF]

Romanian Journal of Infectious Diseases, 2016
Molecular pathology of benign prostatic hyperplasia is multifactorial and involves endocrine, biochemical, immunological interactions. The mechanisms involved in the onset and progression of benign prostatic hyperplasia are: infections, 50 years of age ...
Ilinca Nicolae, Corina-Daniela Ene, Simona Roxana Georgescu   +2 more
doaj   +1 more source

Benign prostatic hyperplasia : Part 1- diagnosis [PDF]

, 2008
Peer reviewedPublisher ...
N'Dow, James Michael Olu, Wilt, Timothy
core   +2 more sources

Effects of inflammatory prostatitis on the development and progression of benign prostatic hyperplasia: A literature review

International journal of urology, 2021
Benign prostatic hyperplasia is a major disease that affects the quality of life of middle‐aged and older men. Although >70% of men aged >70 years have pathological benign prostatic hyperplasia, its pathogenesis and progression remain unclear.
H. Tsunemori, M. Sugimoto
semanticscholar   +1 more source

Hepsin immunohistochemical expression in prostate cancer in relation to Gleason′s grade and serum prostate specific antigen

Indian Journal of Pathology and Microbiology, 2011
Background: Hepsin (HPN), a type II trans-membrane serine protease, has been reported to be one of the most up regulated genes in prostate cancer. The aim of the present study was to find out immuno-histochemistry based phenotypic expression of HPN in ...
Madhu Mati Goel, Dhamita Agrawal, S M Natu, Apul Goel   +3 more
doaj   +1 more source

Efficacy and Side Effects of Drugs Commonly Used for the Treatment of Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia

Frontiers in Pharmacology, 2020
Benign prostatic hyperplasia (BPH) is the most common benign disease of the prostate gland and is caused by benign hyperplasia of the smooth muscle cells and stromal cells in this important gland.
Zhaojun Yu, Hai Yan, Fanghua Xu, Haichao Chao, Leihong Deng, Xiangda Xu, Jianbiao Huang, T. Zeng   +7 more
semanticscholar   +1 more source